State Courts Strike Blows to Criminal DNA Collection Laws in 2014—What to Look for in 2015
By Jennifer Lynch,
Electronic Frontier Foundation
| 01. 05. 2015
DNA can reveal an extraordinary amount of private information about you, including familial relationships, medical history, predisposition for disease, and possibly even behavioral tendencies and sexual orientation. While DNA testing in a criminal context has some benefits—such as supporting innocence claims—the mass, suspicionless collection, testing, and storing of genetic material from large populations creates a danger for privacy that only grows with each new scientific discovery in the field of genomics. In this post, EFF Senior Staff Attorney Jennifer Lynch discusses state and federal cases that addressed DNA collection in 2014, following the Supreme Court’s landmark ruling in Maryland v. King.
2014 was a banner year for DNA cases. In the wake of Maryland v. King—the 2013 U.S. Supreme Court case upholding warrantless, suspicionless DNA collection from arrestees under Maryland state law—the constitutionality of DNA collection in the criminal context has continued to present challenging issues for courts.
Many of the courts that addressed DNA collection in 2014 followed the Supreme Court’s reasoning in King and held that DNA profiling upon arrest is a means...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...